Navigation Links
ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO

repeated). Using these dosing regimens, 64% of rapid and intermediate acetylators and 77% of slow acetylators showed no dose-limiting drug toxicities or dose-delay/holds during treatment.

-- In a population of heavily pretreated patients who were refractory to multiple existing therapies and who had advanced tumors, there was evidence of antitumor activity in a range of tumor types. Three prostate cancers showed a decline in prostate specific antigen (PSA), with one of these achieving a partial response. Two patients with ovarian cancer achieved stable disease accompanied by a decline in the ovarian cancer biomarker CA125. One patient with gastrointestinal stromal tumor (GIST) demonstrated stable disease which was sustained over 18 monthly cycles of amonafide.

Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex said that the results were a significant step in the development of personalized medicines. "The data that Dr Kuhn presented today show very clearly that we now understand the effect of genotype on amonafide metabolism, and that we can dose patients to minimize the side effects of therapy. We are encouraged by the signs of anticancer activity across a range of tumor types in patients who had failed multiple prior therapies, and look forward to progressing Quinamed into further development for indications where the clinical need and commercial potential is greatest."

Quinamed(R) is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes and obesity. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex's lead compound, Ceflatonin(R), is currently in phase
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:12/1/2008)... ROCKVILLE, Md., Dec. 1 ...rts publication in The Lancet , one of the world,...ials of its novel circadian regulator, experimenta... by Rajaratnam et al(1) is entitled "Melatonin ago...after sleep-time shift: two randomised controlled ...
(Date:12/1/2008)... St. Jude study shows the Prox1 gene is a two-way...thelial cells to be reprogrammed so that they lose...lial cells , , MEMPHIS, Tenn., Dec. 1 /PRNe...dren,s Research Hospital have discovered that a ce...ge its identity that it requires the constant expr...
(Date:12/1/2008)... ATLANTA, Dec. 1 GeoVax...a-based biotechnology company developing,human va...eficiency Virus) and,other infectious agents, ann...,Vaccine Trials will take place in twelve sites a...onducted in collaboration with The National Instit...
(Date:11/28/2008)... INDIANAPOLIS, Nov. 28 ...n its supplemental New Drug Application (sNDA) fro... Cymbalta(R) (duloxetine HCl),for the management ...cation in,the first half of 2009, adding data fro...osteoarthritis pain of the knee. , The deci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 1UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 2UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 3UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 1NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 2NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 3NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 5Shape Shifting on Veterans Day 5756 1Shape Shifting on Veterans Day 5756 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 1More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 3More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 4
...LE, Calif., April 16, 2007 /PRNewswire-FirstCall/ ...anism of action of,its anti-cancer agent BZL101, w...r late stage breast cancer at the American,Associa...os Angeles,Convention Center in Los Angeles, CA, A...n will describe the pathway for,cancer cell apopto...
...agonist Demonstrates Clinical Activity, a Novel Me...other HCV Inhibitors-, NEW HAVEN, Conn., April 16,...uticals, Inc. today announced the presentation of,... one of,Achillion,s NS4A antagonists, ACH-806, for...n at the 42nd Annual Meeting of the,European Assoc...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:12/2/2008)...stCall/ -- Genoptix, Inc. (Nasdaq: GXDX ), a spe...nced the Company,s participation at the RBC Capita...take place at the Westin New York Hotel at Times S...ccitelli, COO and executive vice president of Geno...conference on Wednesday, December 10, beginning at...
(Date:12/2/2008).../ -- LCA-Vision Inc. (Nasdaq:, LCAV ), a leading...r the,LasikPlus(R) brand, today announced that me...nt at RBC Capital Markets, 2008 Healthcare Confere...astern time. The conference is,being held at The... archived,webcast of the event will be available ...
(Date:12/2/2008)... -- In response to the commentary entitled "Cod Li...Infections, and the Vitamin D Deficiency Epidemic"...ement experts, Nordic Naturals announced today tha...promise to consumers and actually offer healthy om...itamin A. According to Karin Yien, MD, Nordic Natu...
(Date:12/2/2008)...hcare group at Frost & Sullivan,( http://www....t it will be,hosting an interactive analyst brief... on 11 December 2008 at 3pm GMT. , (Logo: ...O ) , With most diagnostic cardiology marke...are faced with an immense challenge of keeping pro...
Breaking Medicine News(10 mins):Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2
...in Andhra Pradesh have hit on a novel method of pr...n thousands of residents opened their// newspapers...three condoms on the front page. "Earlier we dist..., through milk vendors and at pan (tobacco) shops ...
...ticals, a leading player in the Indian drug indust...d and Drug Authority (FDA) for three// of its abbr...me. Orchid will be launching this product in the... partner, Apotex, the Chennai-based company said i...
...ts are high in saturated and trans fats, a high in...ed rate of decline in thinking, learning// and mem... essential for brain development and function, an ...ole in the development of brain plaques associated...
...British Medical Journal, researchers at Oxford Uni...er cent in the consumption of common foods// conta...increase in coronary heart disease. Trans fats ar...shelf life of food and is added to most fast foods...
Other Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
...es BchiVac V-500 with Vacuum Controller V-800 Ef... switching mechanism turns V-500 on and off as nee...ing Model V-500 is a powerful PTFE membrane vacu...s. Applications Ideally suited for use with up ...
...1000 is a new addition to the powerful PTFE membra...ce pump can achieve an ultimate vacuum of 1 mbar o... with vacuum drying ovens and centrifugal vacuum c...size up to industrial size rotary evaporators Bchi...
...500 is a powerful PTFE membrane vacuum pump design...ns Ideally suited for use with up to two rotary ...ents including vacuum ovens, concentrators, gel dr...es PEEK head resistant to chemicals and heat load...
Medicine Products: